Maternal use of selective serotonin reuptake inhibitors, fetal growth, and risk of adverse birth outcomes.
about
A meta-analysis of the relationship between antidepressant use in pregnancy and the risk of preterm birth and low birth weightEpidemiology of child psychopathology: major milestonesBone growth in juvenile rhesus monkeys is influenced by 5HTTLPR polymorphisms and interactions between 5HTTLPR polymorphisms and fluoxetineMonoamine-sensitive developmental periods impacting adult emotional and cognitive behaviors.Rate of Chiari I malformation in children of mothers with depression with and without prenatal SSRI exposure.Early-life serotonin dysregulation affects the migration and positioning of cortical interneuron subtypes.Antepartum depression severity is increased during seasonally longer nights: relationship to melatonin and cortisol timing and quantity.Perinatal outcomes of pregnancies complicated by maternal depression with or without selective serotonin reuptake inhibitor therapyRecent advances in understanding maternal perinatal mood disorders.Does fetal exposure to SSRIs or maternal depression impact infant growth?Antidepressant use in pregnant and postpartum womenParenting enhancement, interpersonal psychotherapy to reduce depression in low-income mothers of infants and toddlers: a randomized trial.Lack of tryptophan hydroxylase-1 in mice results in gait abnormalities.The effect of antenatal depression and selective serotonin reuptake inhibitor treatment on nerve growth factor signaling in human placenta.Practitioner review: maternal mood in pregnancy and child development--implications for child psychology and psychiatry.Preterm birth and antidepressant medication use during pregnancy: a systematic review and meta-analysis.Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design.Prenatal depression and adverse birth outcomes: an updated systematic review.Effects of Citalopram on Sutural and Calvarial Cell Processes.Effects of Fluoxetine on Human Embryo Development.Is the Risk of Preterm Birth and Low Birth Weight Affected by the Use of Antidepressant Agents during Pregnancy? A Population-Based InvestigationMaternal psychiatric disorders and risk of preterm birthParental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case-control study.The effects of maternal depression and maternal selective serotonin reuptake inhibitor exposure on offspringSerotonin homeostasis and serotonin receptors as actors of cortical construction: special attention to the 5-HT3A and 5-HT6 receptor subtypes.Of rodents and humans: A comparative review of the neurobehavioral effects of early life SSRI exposure in preclinical and clinical research.Perinatal Maternal Mental Health, Fetal Programming and Child Development.Antidepressant exposure in pregnancy and risk of autism spectrum disorders.Central nervous system effects of prenatal selective serotonin reuptake inhibitors: sensing the signal through the noise.Effects of maternal psychotropic drug dosage on birth outcomes.Serotonin-related pathways and developmental plasticity: relevance for psychiatric disorders.Maternal use of antidepressant or anxiolytic medication during pregnancy and childhood neurodevelopmental outcomes: a systematic review.Prenatal SSRI exposure: Effects on later child development.The safety of serotonin-noradrenaline reuptake inhibitors (SNRIs) in pregnancy and breastfeeding: a comprehensive review.Use of psychotropic drugs during pregnancy and breast-feeding.The concordance between self-reported medication use and pharmacy records in pregnant women.Use of antidepressant medication in pregnancy and adverse neonatal outcomes: A population-based investigation.A rock and a hard place: The selective serotonin reuptake inhibitor dilemmas in addressing perinatal mood and anxiety disorders.Sertraline use in the first trimester and risk of congenital anomalies: a systemic review and meta-analysis of cohort studies.PRENATAL EXPOSURE TO MATERNAL AND PATERNAL DEPRESSIVE SYMPTOMS AND BRAIN MORPHOLOGY: A POPULATION-BASED PROSPECTIVE NEUROIMAGING STUDY IN YOUNG CHILDREN.
P2860
Q24623163-74E5C8AB-190E-4F6F-B7B7-A61F185298DEQ28257503-A25EB0F0-FB25-4C9C-B1E8-8C3847B1D581Q28384165-3A08F7B1-9C00-4A6E-8AAC-F96AB7271990Q30395001-4E017962-E586-4391-8A82-05FDF092D913Q30595737-56B508CB-9915-4945-8D95-72C8E974427BQ30823860-41C1E016-17C9-44CB-B43A-6CFF17564E62Q33698803-0D9B79CC-9A48-41BE-8DFA-8AC281C91464Q33745085-99AB5B8C-C523-42F3-A0CA-056C40AF724FQ33806570-F37C0BA7-64B6-4EB2-BF7E-4129D2C24F4AQ33959971-23FB42EA-A015-46E7-AA29-5FDBE9AD1FE0Q34068023-670C68E6-A180-4E56-B25B-AAB97748A259Q34533776-9F7DB9DE-BA4A-4ED2-B994-662F3EE3FFF5Q34630258-607AD74E-714D-4903-B145-BA8E855174B7Q35000963-DF685679-AC51-4A19-AA77-097F53252086Q35017628-47390187-B3F3-4FFB-B919-13328481582FQ35132422-4DFA20E0-A8AE-426A-9A89-591D7B0743BEQ35541040-883AB21C-69FE-482F-82A5-A6DC2F3F59E0Q35661005-52A9B291-8F67-4B1B-B5CA-5634ECBC3CF2Q35796871-CC116734-4DAE-4E4D-94AA-004BB67BCBD3Q36068009-2F579F06-A92E-4C52-8BD8-4B31571C1937Q36225011-04F91BC9-4F00-47CC-8F41-108F20C26EDFQ36396118-A1BC036B-9893-4648-88FE-96EB198D74B6Q36779955-F58E44B5-DB97-43D4-87BB-BE62404236B6Q36860205-09392258-803F-471C-A60B-3A0B6988FA39Q36939119-6DD409F0-C20A-4989-A9BF-59ADB91D3918Q37058701-67E8DD64-DE89-4530-96DB-4612104EFF07Q37069604-033CECA2-8CBB-4C12-A75F-0B82DD98F6A8Q37320948-5E9C6C16-4B87-4699-B43D-FE77B9414F5CQ37337705-D1DD3DAF-C571-48B2-8256-6EF485C5EC5FQ37397151-2D20BEB8-E268-49CB-AC94-A3B60C76546BQ37699993-19219660-247F-4082-BE48-8F8AB3E20497Q38215072-3B31B486-9D4C-4F5F-9CEB-097AEE844DEEQ38236646-87D1F242-0A18-481F-8CA5-C6172DA2B1D5Q38382317-809C4A37-0CF3-4900-BE72-5C69E14EE09DQ38582061-F98CD34B-AA50-4670-A733-40FB80C45F75Q38660888-8D888EA2-664C-479C-8CA7-EFC15CE6B4CCQ38736763-97DFF0B0-4881-4DAD-B2FE-EAD647BF1723Q38784504-11D2070A-7DFE-48AA-8FE1-CC4C1E77526EQ38988107-1B90F589-B1BF-439F-8CA6-AC6121D814EEQ39779745-B36759F7-44AF-49BC-82BE-12F262E9E522
P2860
Maternal use of selective serotonin reuptake inhibitors, fetal growth, and risk of adverse birth outcomes.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Maternal use of selective sero ...... isk of adverse birth outcomes.
@en
Maternal use of selective sero ...... isk of adverse birth outcomes.
@nl
type
label
Maternal use of selective sero ...... isk of adverse birth outcomes.
@en
Maternal use of selective sero ...... isk of adverse birth outcomes.
@nl
prefLabel
Maternal use of selective sero ...... isk of adverse birth outcomes.
@en
Maternal use of selective sero ...... isk of adverse birth outcomes.
@nl
P2093
P50
P1433
P1476
Maternal use of selective sero ...... isk of adverse birth outcomes.
@en
P2093
Bruno H C Stricker
Eric A P Steegers
Frank C Verhulst
Hanan El Marroun
Sabine J Roza
Tonya J H White
Vincent W V Jaddoe
P304
P356
10.1001/ARCHGENPSYCHIATRY.2011.2333
P407
P577
2012-07-01T00:00:00Z